Christina Engelke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Christina Engelke has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Christian Schmidt-Kraepelin
Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine-University Dusseldorf, Düsseldorf, Germany
3 shared publications- Christian Schmidt-Kraepelin
Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany
3 shared publications - Georg Winterer
Department of Anesthesiology and Intensive Care Medicine | CCM | CVK, Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Berlin, Germany
3 shared publications Joachim Cordes
Kaiserswerther Diakonie, Duesseldorf, Germany
3 shared publications- Joachim Cordes
Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany
3 shared publications - Thomas Wobrock
Department of Psychiatry and Psychotherapy, Georg-August-University Göttingen, Göttingen, Germany; Department of Psychiatry and Psychotherapy, County Hospitals Darmstadt-Dieburg, Groß-Umstadt, Germany
3 shared publications
Latest Publications
- Open Access
- 1 April 2025
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 21, 955-964
Beyond Anxiety and Depression: Multidimensional Psychiatric Screening for Neurological Patients Based on HADS and BSI-53
Objective: Although neurological patients are known to suffer from psychiatric comorbidities, appropriate, cost-effective, standardized screening measures are still scarce in clinical practice. We examined a multidimensional psychiatric screening for neurological patients. Methods: We report a retrospective analysis of multidimensional psychiatric screening using the HADS-D and the BSI-53 in 437 consecutive neurological inpatients. The HADS-D describes depressive and anxiety symptoms, while the BSI-53 expands the symptom clusters associated with psychiatric disorders by somatization, obsessive-compulsion, interpersonal sensitivity, hostility, paranoid ideation, psychoticism and global measures of mental distress. Patients were separated in diagnostic groups (vascular, demyelinating, degenerative, epileptic, other) with regard to their diagnosis. Results: Our results corroborate previous findings of high prevalence of psychiatric symptoms particularly in younger patients (< 60 years). Furthermore, 27.2% were above the HADS-D cut-off for anxiety and 25.4% for depression. We found no differences between diagnostic groups. Importantly, we also show that neurological patients suffer from mental distress beyond anxiety and depression, around 16– 30% depending on age and gender. Conclusion: We have shown that a notable proportion of neurological patients report psychiatric symptoms, thus emphasizing the importance of a thorough, multidimensional psychiatric screening in neurological patients. Trial Registration Number: DRKS00030528, date of registration: 2022-11-04 retrospectively registered.
- 1 April 2025
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 21, 955-964
Open AccessBeyond Anxiety and Depression: Multidimensional Psychiatric Screening for Neurological Patients Based on HADS and BSI-53
Objective: Although neurological patients are known to suffer from psychiatric comorbidities, appropriate, cost-effective, standardized screening measures are still scarce in clinical practice. We examined a multidimensional psychiatric screening for neurological patients. Methods: We report a retrospective analysis of multidimensional psychiatric screening using the HADS-D and the BSI-53 in 437 consecutive neurological inpatients. The HADS-D describes depressive and anxiety symptoms, while the BSI-53 expands the symptom clusters associated with psychiatric disorders by somatization, obsessive-compulsion, interpersonal sensitivity, hostility, paranoid ideation, psychoticism and global measures of mental distress. Patients were separated in diagnostic groups (vascular, demyelinating, degenerative, epileptic, other) with regard to their diagnosis. Results: Our results corroborate previous findings of high prevalence of psychiatric symptoms particularly in younger patients (< 60 years). Furthermore, 27.2% were above the HADS-D cut-off for anxiety and 25.4% for depression. We found no differences between diagnostic groups. Importantly, we also show that neurological patients suffer from mental distress beyond anxiety and depression, around 16– 30% depending on age and gender. Conclusion: We have shown that a notable proportion of neurological patients report psychiatric symptoms, thus emphasizing the importance of a thorough, multidimensional psychiatric screening in neurological patients. Trial Registration Number: DRKS00030528, date of registration: 2022-11-04 retrospectively registered.
- Open Access
- 1 July 2020
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 148 (7-8) , 447-450
Attitudes towards repetitive transcranial magnetic stimulation among depressive patients and medical students
Introduction/Objective Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and safe brain stimulation method for the treatment of therapy resistant depression in adulthood. The German 53 guideline for unipolar depression recommends the use of high frequency rTMS of the left dorsolateral prefrontal cortex for depressive patients who did not respond primarily to antidepressant pharmacotherapy. Although a number of meta-analyses demonstrated its antidepressant efficacy on a high evidence level, rTMS is rarely offered to patients with mental disorders in German psychiatric hospitals. Methods We introduced a questionnaire-based survey examining patients' (n = 122) and medical students' (n = 53) attitude towards rTMS. The questionnaire consisted of 10 questions with a 5-point Likert-scale. When testing for group differences, we conducted chi(2) tests. Results The majority of students and patients are not aware of rTMS as a psychiatric treatment of depression, with more patients than students not being aware (chi(2)(1) = 9.462, p = 0.002; 39.3% vs. 17%). However, participants wish to be informed in more detail about rTMS. In general, positive attitudes cover the assumption of safety, while negative attitudes show concerns regarding the efficacy and a lack of trust in the method, mainly due to the fear of irreversible brain damage. Most participants would rather take psychiatric medication than rTMS. rTMS was assumed to be a helpful [chi(2) (2) = 16.710, p < 0.001 (patients: 32.8% vs. students: 5.7%)) and well-tolerated treatment [chi(2) (1) = 9.110, p = 0.003 (36.1% vs. 15.1%)) significantly more often by patients than by students. Conclusion Our results show a clear need for more information on rTMS as a psychiatric treatment for patients and medical students to fight present prejudices and negative assumptions so that this treatment method with fewer side effects than medication may be used more often.
- 1 July 2020
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 148 (7-8) , 447-450
Open AccessAttitudes towards repetitive transcranial magnetic stimulation among depressive patients and medical students
Introduction/Objective Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and safe brain stimulation method for the treatment of therapy resistant depression in adulthood. The German 53 guideline for unipolar depression recommends the use of high frequency rTMS of the left dorsolateral prefrontal cortex for depressive patients who did not respond primarily to antidepressant pharmacotherapy. Although a number of meta-analyses demonstrated its antidepressant efficacy on a high evidence level, rTMS is rarely offered to patients with mental disorders in German psychiatric hospitals. Methods We introduced a questionnaire-based survey examining patients' (n = 122) and medical students' (n = 53) attitude towards rTMS. The questionnaire consisted of 10 questions with a 5-point Likert-scale. When testing for group differences, we conducted chi(2) tests. Results The majority of students and patients are not aware of rTMS as a psychiatric treatment of depression, with more patients than students not being aware (chi(2)(1) = 9.462, p = 0.002; 39.3% vs. 17%). However, participants wish to be informed in more detail about rTMS. In general, positive attitudes cover the assumption of safety, while negative attitudes show concerns regarding the efficacy and a lack of trust in the method, mainly due to the fear of irreversible brain damage. Most participants would rather take psychiatric medication than rTMS. rTMS was assumed to be a helpful [chi(2) (2) = 16.710, p < 0.001 (patients: 32.8% vs. students: 5.7%)) and well-tolerated treatment [chi(2) (1) = 9.110, p = 0.003 (36.1% vs. 15.1%)) significantly more often by patients than by students. Conclusion Our results show a clear need for more information on rTMS as a psychiatric treatment for patients and medical students to fight present prejudices and negative assumptions so that this treatment method with fewer side effects than medication may be used more often.
- 5 November 2019
- Published by SAGE Publications in The International Journal of Psychiatry in Medicine
- Vol. 55 (2) , 114-122
Hormone replacement therapy with L-thyroxine promotes working memory and concentration in thyroidectomized female patients after differentiated thyroid carcinoma
Objective: It is well established that long-term hypothyroidism is associated with cognitive deficits. Based on recent literature, we hypothesized that pharmacologically induced euthyroidism would lead to improved cognitive performance compared to a hypothyroid state. Methods: We analyzed data from 14 nondepressed thyroidectomized female patients after differentiated thyroid carcinoma during hypothyroidism (due to a four-week withdrawal of thyroid hormone, T1) and euthyroidism brought about by substitution with L-thyroxine (T2). At both measurement points, patients completed a cognitive test battery as our dependent measure and Beck’s Depression Inventory to control depressive states. Results: A Wilcoxon signed-rank tests revealed a significant improvement in the Rey–Osterrieth complex figure test (cognitive reproduction), Z = −3.183, p = 0.001, and the D2 concentration score, Z = −1.992, p = 0.046 in euthyroidism compared to hypothyroidism. Conclusions: Our results confirm that hormone replacement therapy with L-thyroxine promotes cognitive reproduction and concentration in thyroidectomized female patients after differentiated thyroid carcinoma.
- 5 November 2019
- Published by SAGE Publications in The International Journal of Psychiatry in Medicine
- Vol. 55 (2) , 114-122
Hormone replacement therapy with L-thyroxine promotes working memory and concentration in thyroidectomized female patients after differentiated thyroid carcinoma
Objective: It is well established that long-term hypothyroidism is associated with cognitive deficits. Based on recent literature, we hypothesized that pharmacologically induced euthyroidism would lead to improved cognitive performance compared to a hypothyroid state. Methods: We analyzed data from 14 nondepressed thyroidectomized female patients after differentiated thyroid carcinoma during hypothyroidism (due to a four-week withdrawal of thyroid hormone, T1) and euthyroidism brought about by substitution with L-thyroxine (T2). At both measurement points, patients completed a cognitive test battery as our dependent measure and Beck’s Depression Inventory to control depressive states. Results: A Wilcoxon signed-rank tests revealed a significant improvement in the Rey–Osterrieth complex figure test (cognitive reproduction), Z = −3.183, p = 0.001, and the D2 concentration score, Z = −1.992, p = 0.046 in euthyroidism compared to hypothyroidism. Conclusions: Our results confirm that hormone replacement therapy with L-thyroxine promotes cognitive reproduction and concentration in thyroidectomized female patients after differentiated thyroid carcinoma.
- 14 June 2019
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 39 (4) , 357-361
Attitudes Toward Long-Term Medication Use—A Comparison Between Concerned Populations and a Sample From the German General Population
The present study was conducted to investigate the difference in attitudes toward psychiatric drugs, long-term medication, and depot formulations between psychiatric patients and patient-related groups and the German general public. Different groups (n = 50 patients, n = 34 relatives of patients, n = 42 psychiatrists, n = 70 medical students, and n = 58 psychiatric nursing professionals) were surveyed using a questionnaire to investigate their attitude toward depot medication and compared with matched participants from the German general public. Patients did not differ from their matched controls regarding their attitude toward potential reasons to reject a depot, whereas psychiatrists (P = 0.002) and nursing staff (P = 0.003) were more concerned about patients fearing an injection than their matched controls. Psychiatrists and psychiatric nurses were significantly more concerned about giving an (intragluteal) injection because of concerns about patients' fears of this administration method than their matched controls. In contrast, patients' concerns about receiving an injection did not differ from their matched controls. Furthermore, we found that psychiatrists tended to believe that giving an injection might be time-consuming than giving oral medication. These results may emphasize the fact that the low rate of depot medication use is derived from subjective reservations of medical staff rather than actual negative attitudes or fears of patients.
- 14 June 2019
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 39 (4) , 357-361
Attitudes Toward Long-Term Medication Use—A Comparison Between Concerned Populations and a Sample From the German General Population
The present study was conducted to investigate the difference in attitudes toward psychiatric drugs, long-term medication, and depot formulations between psychiatric patients and patient-related groups and the German general public. Different groups (n = 50 patients, n = 34 relatives of patients, n = 42 psychiatrists, n = 70 medical students, and n = 58 psychiatric nursing professionals) were surveyed using a questionnaire to investigate their attitude toward depot medication and compared with matched participants from the German general public. Patients did not differ from their matched controls regarding their attitude toward potential reasons to reject a depot, whereas psychiatrists (P = 0.002) and nursing staff (P = 0.003) were more concerned about patients fearing an injection than their matched controls. Psychiatrists and psychiatric nurses were significantly more concerned about giving an (intragluteal) injection because of concerns about patients' fears of this administration method than their matched controls. In contrast, patients' concerns about receiving an injection did not differ from their matched controls. Furthermore, we found that psychiatrists tended to believe that giving an injection might be time-consuming than giving oral medication. These results may emphasize the fact that the low rate of depot medication use is derived from subjective reservations of medical staff rather than actual negative attitudes or fears of patients.
- 1 December 2018
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 38 (6) , 612-617
Attitudes Concerning Antipsychotic Depot Medication in the German General Population
Background Treatment of schizophrenia with depot medication has advantages compared with oral medication, and among these include an improved compliance. Despite such advantages, prescription rates in many European countries are lower than 20%. The aim of this survey was to study the attitudes toward depot medication among the German general population. To the best of our knowledge, only selective samples have been investigated up until now. Methods A representative sample of 754 people were interviewed via telephone by a professional market research and polling organization. The questionnaire queried demographic characteristics, experience with medication, and the treatment of mental disorders. Subjects' attitudes toward medication in general, long-term medication, and depot medication were surveyed. Results Most (66.7%) of the subjects stated that they would be willing to receive depot medication. Subjects who experienced the treatment of mental disorders were more likely to be willing to receive depot medication. Among the reasons for not using depot medication, “fear of injection” (66.3%) and “more self-control when taking medication as tablets” (48.9%) were stated as the most frequent reasons. Conclusions This study found a good acceptance of antipsychotic depot medication among the German general population in terms of willingness to receive such treatment. We argue that the clinical practitioners' assumptions that depot formulations would be refused by many patients are unsubstantiated.
- 1 December 2018
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 38 (6) , 612-617
Attitudes Concerning Antipsychotic Depot Medication in the German General Population
Background Treatment of schizophrenia with depot medication has advantages compared with oral medication, and among these include an improved compliance. Despite such advantages, prescription rates in many European countries are lower than 20%. The aim of this survey was to study the attitudes toward depot medication among the German general population. To the best of our knowledge, only selective samples have been investigated up until now. Methods A representative sample of 754 people were interviewed via telephone by a professional market research and polling organization. The questionnaire queried demographic characteristics, experience with medication, and the treatment of mental disorders. Subjects' attitudes toward medication in general, long-term medication, and depot medication were surveyed. Results Most (66.7%) of the subjects stated that they would be willing to receive depot medication. Subjects who experienced the treatment of mental disorders were more likely to be willing to receive depot medication. Among the reasons for not using depot medication, “fear of injection” (66.3%) and “more self-control when taking medication as tablets” (48.9%) were stated as the most frequent reasons. Conclusions This study found a good acceptance of antipsychotic depot medication among the German general population in terms of willingness to receive such treatment. We argue that the clinical practitioners' assumptions that depot formulations would be refused by many patients are unsubstantiated.
- 1 February 2018
- Published by Elsevier in Schizophrenia Research
- Vol. 192, 481-484
Letter to the Editor: Influence of rTMS on smoking in patients with schizophrenia
- 1 February 2018
- Published by Elsevier in Schizophrenia Research
- Vol. 192, 481-484
Letter to the Editor: Influence of rTMS on smoking in patients with schizophrenia
- 1 March 2017
- Published by Elsevier in Schizophrenia Research
- Vol. 181, 38-42
Prevalence of metabolic syndrome in female and male patients at risk of psychosis
- 1 March 2017
- Published by Elsevier in Schizophrenia Research
- Vol. 181, 38-42
Prevalence of metabolic syndrome in female and male patients at risk of psychosis